PCYT1A is a lineage-specific metabolic vulnerability in monocytic acute myeloid leukemia

Cancer is often described as a disease of broken genes, where the instructions for cell growth and division go haywire. But for doctors treating a specific and aggressive form of blood cancer called acute myeloid leukemia, the problem is not just that the cells are growing too fast, but that they are stubbornly resistant to the best treatments available. This resistance is particularly severe in a subtype known as monocytic leukemia, where the cancer cells resemble immature white blood cells that are supposed to fight infection. These cells have proven difficult to kill with standard chemotherapy or newer targeted drugs, leaving patients with few options. To find a way forward, scientists are increasingly looking beyond the genetic mutations that cause the disease and instead examining the unique metabolic habits of the cancer cells themselves—the specific chemical fuels and building blocks they need to survive. By understanding what makes these cells tick, researchers hope to find a way to starve them or disrupt their internal machinery without harming healthy tissue.

A team of researchers at the University of Tokyo and other institutions has identified such a weakness in monocytic leukemia. They discovered that these cancer cells are uniquely dependent on a specific enzyme called PCYT1A to build the fats that make up their cell membranes. This dependency is not a random flaw but a result of how the cells are programmed. In most other types of cells, there is a backup system: if the primary enzyme fails, a nearly identical partner enzyme can step in to do the job. However, in monocytic leukemia cells, the gene for this backup partner is switched off. This leaves the cancer cells with only one way to make the fats they need. When the researchers removed the primary enzyme, the cells could not compensate, leading to their collapse.

The discovery began with a massive digital search. The scientists used a public database containing data from over a thousand different cancer cell lines to compare how essential various genes were for cell survival. They created a custom computer program to sort these cells into groups based on their specific genetic features and lineage. When they compared leukemia cells with a specific genetic rearrangement known as KMT2A-r against those without it, one gene stood out as critically important only in the rearranged group. That gene was PCYT1A. Further analysis revealed that this vulnerability was not limited to just that one genetic rearrangement. Instead, it was a defining feature of the monocytic lineage itself. Whether the cells carried the KMT2A rearrangement or not, if they had the characteristics of monocytic leukemia, they relied heavily on PCYT1A.

To understand why this was the case, the team looked at the backup partner enzyme, PCYT1B. In normal cells and in other types of leukemia, both enzymes are active, providing a safety net. But in monocytic leukemia cells, the gene for PCYT1B is silenced. This creates a situation of synthetic lethality, a concept where two things are harmless on their own but deadly when combined. Here, the cancer cell is harmless because it has the primary enzyme, but it is also harmless because the backup is missing. The cell survives only because the primary enzyme is working. If you remove that single primary enzyme, the cell has no way to make the essential fats it needs to build its outer shell.

The researchers tested this idea in the lab by using a gene-editing tool to disable PCYT1A in various leukemia models. In cells that resembled monocytic leukemia, the loss of this enzyme caused the cells to stop growing, begin to mature into normal-looking cells, and eventually die. In contrast, cells from other types of leukemia that still had their backup enzyme were largely unaffected. This confirmed that the vulnerability was specific to the monocytic lineage. The team also observed that when the primary enzyme was removed, the cells tried to compensate by upregulating a different pathway that uses a molecule called methionine to make fats. However, this backup route was not enough to save the cells in the long run. Over time, the cells ran out of the specific fats they needed, their internal membranes became unstable, and they died.

To see if this finding held up in a living organism, the researchers injected leukemia cells into mice. In mice given cells where the enzyme was disabled, the cancer failed to spread, and the animals lived significantly longer than those given normal cancer cells. The team also used patient-derived cells, which are leukemia samples taken directly from people and grown in mice, to confirm the results. Even in these complex, real-world models, disabling the enzyme stopped the cancer from growing. The study also showed that the cancer cells were "addicted" to choline, a nutrient they import from their environment to build their fats. This addiction was linked to the expression of specific transporters that were much higher in monocytic leukemia than in other types, suggesting that the cells had hijacked a normal biological process to fuel their rapid growth.

Finally, the team explored whether this weakness could be exploited with drugs. Since there is no drug that targets only the primary enzyme, they used a compound called miltefosine, which blocks the entire pathway of fat synthesis. This drug killed the monocytic leukemia cells in the lab. More importantly, when combined with existing leukemia treatments like venetoclax or standard chemotherapy, the drug worked much better than either treatment alone. The combination caused a powerful synergistic effect, meaning the drugs worked together to kill the cancer cells more effectively than the sum of their individual parts.

The study suggests that the key to treating this difficult form of leukemia lies in targeting the cell's inherent metabolic architecture. By focusing on the specific way monocytic cells are wired to make fats, and exploiting the fact that they lack a backup system, it may be possible to overcome the resistance that currently makes these cancers so hard to treat. While the researchers note that developing a drug that targets only the primary enzyme is challenging due to its similarity to the backup enzyme, the findings provide a strong rationale for exploring new metabolic therapies. The work highlights that understanding the unique biological identity of a cancer subtype can reveal vulnerabilities that are invisible when looking only at genetic mutations, offering a new path forward for patients who have run out of options.